Successful anti-hepatitis C virus therapy with telaprevir in an HIV/hepatitis C virus co-infected patient with a severe recurrence of hepatitis C virus infection on the liver graft.
We report, for the first time, the outcome of anti-hepatitis C virus (HCV) triple therapy with telaprevir in an HIV/HCV co-infected transplanted patient. After liver transplantation, the patient experienced a severe HCV recurrence with fibrosing cholestatic hepatitis, and anti-HCV therapy with pegylated interferon alpha 2a, ribavirin and telaprevir was initiated. A sustained virological response was achieved after 48 weeks of anti-HCV therapy. Drug-drug interactions between antiretroviral therapy, immunosuppressive agents and anti-HCV therapy could be managed.
aAP-HP, Hôpital Paul Brousse, Centre Hépato-Biliaire bUniversity Paris-Sud, UMR-S 785 cInserm, Unité 785, Villejuif dAP-HP, HôpitalBicêtre, Pharmacie Clinique eAP-HP, Hôpital Bicêtre, Service de Médecine Interne, Immunologie et Maladies Infectieuses, Le Kremlin Bicêtre fAP-HP Hôpital Paul Brousse, Service de Virologie gAP-HP, Hôpital Paul Brousse, Service Anatomie Pathologique hAP-HP, Hôpital Paul Brousse, Pharmacie Clinique, Villejuif iAP-HP, GH Xavier Bichat-Claude Bernard, Laboratoire de Toxicologie et Pharmacocinétique jUniversité Paris, Paris kHepatinov, Villejuif, France.
Teresa M
TM
Antonini
Valerie
V
Furlan
Elina
E
Teicher
Stephanie
S
Haim-Boukobza
Mylene
M
Sebagh
Audrey
A
Coilly
Laurence
L
Bonhomme-Faivre
Gilles
G
Peytavin
Anne-Marie
AM
Roque-Afonso
Daniel
D
Vittecoq
Didier
D
Samuel
Anne-Marie
AM
Taburet
Jean-Charles
JC
Duclos-Vallée
D000998:Antiviral Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination / Q000379:methods; D005260:Female; D015658:HIV Infections / Q000150:complications*; D006526:Hepatitis C / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use; D016031:Liver Transplantation; D008875:Middle Aged; D009842:Oligopeptides / Q000627:therapeutic use*; D011092:Polyethylene Glycols / Q000627:therapeutic use; D012367:RNA, Viral / Q000097:blood; D011994:Recombinant Proteins / Q000627:therapeutic use; D012254:Ribavirin / Q000627:therapeutic use; D014180:Transplantation; D016896:Treatment Outcome; D019562:Viral Load
D000998:Antiviral Agents; D016898:Interferon-alpha; D009842:Oligopeptides; D012367:RNA, Viral; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C486464:telaprevir; C100416:peginterferon alfa-2a